000120471 001__ 120471
000120471 005__ 20240228145447.0
000120471 0247_ $$2doi$$a10.1002/gcc.22427
000120471 0247_ $$2pmid$$apmid:27750395
000120471 0247_ $$2ISSN$$a1045-2257
000120471 0247_ $$2ISSN$$a1098-2264
000120471 0247_ $$2altmetric$$aaltmetric:22274813
000120471 037__ $$aDKFZ-2017-00900
000120471 041__ $$aeng
000120471 082__ $$a570
000120471 1001_ $$aLeichsenring, Jonas$$b0
000120471 245__ $$aSynonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
000120471 260__ $$aNew York, NY$$bWiley-Liss$$c2017
000120471 3367_ $$2DRIVER$$aarticle
000120471 3367_ $$2DataCite$$aOutput Types/Journal article
000120471 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510748486_10583
000120471 3367_ $$2BibTeX$$aARTICLE
000120471 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120471 3367_ $$00$$2EndNote$$aJournal Article
000120471 520__ $$aPatients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9%) carried EGFR mutations targetable by TKIs (30.4% male patients, median age 65.1 y, 19.6% smokers with 12.8 median pack years). Seventy-nine patients (77.5%) received TKI therapy either as a first- or second-line therapy. Of the 102 EGFR-mutant tumors, 72 (70.6%) exhibited the p.Q787Q polymorphism and another 12 (11.8%) cases with p.Q787Q harbored an additional TKI insensitive mutation (p.T790M). The polymorphism was neither associated with classic clinicopathological parameters nor with overall survival (21.1 months vs. 20.1 months; P-value = 0.91) or clinical response (P-value = 0.122). The patients with p.T790M had worse survival compared to EGFR activating mutation carriers with and without p.Q787Q when analyzed as a separate group (27.5 months, P-value = 0.02). In conclusion, p.Q787Q is neither a suitable prognostic nor predictive biomarker for ADC patients receiving anti-EGFR therapy in first- or second-line of therapy. © 2016 Wiley Periodicals, Inc.
000120471 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000120471 588__ $$aDataset connected to CrossRef, PubMed,
000120471 7001_ $$aVolckmar, Anna-Lena$$b1
000120471 7001_ $$aMagios, Nikolaus$$b2
000120471 7001_ $$0P:(DE-He78)fbd667fcaef393a09fce8e13ac2098fc$$aMorais de Oliveira, Cristiano Manuel$$b3$$udkfz
000120471 7001_ $$aPenzel, Roland$$b4
000120471 7001_ $$aBrandt, Regine$$b5
000120471 7001_ $$0P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9$$aKirchner, Martina$$b6$$udkfz
000120471 7001_ $$aBozorgmehr, Farastuk$$b7
000120471 7001_ $$0P:(DE-He78)7ea5796e902013b7f64003d16dd14df7$$aThomas, Michael$$b8$$udkfz
000120471 7001_ $$0P:(DE-HGF)0$$aSchirmacher, Peter$$b9
000120471 7001_ $$aWarth, Arne$$b10
000120471 7001_ $$aEndris, Volker$$b11
000120471 7001_ $$0P:(DE-HGF)0$$aStenzinger, Albrecht$$b12$$eLast author
000120471 773__ $$0PERI:(DE-600)1492641-6$$a10.1002/gcc.22427$$gVol. 56, no. 3, p. 214 - 220$$n3$$p214 - 220$$tGenes, chromosomes & cancer$$v56$$x1045-2257$$y2017
000120471 909CO $$ooai:inrepo02.dkfz.de:120471$$pVDB
000120471 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fbd667fcaef393a09fce8e13ac2098fc$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000120471 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120471 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7ea5796e902013b7f64003d16dd14df7$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000120471 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000120471 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000120471 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000120471 9141_ $$y2017
000120471 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120471 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGENE CHROMOSOME CANC : 2015
000120471 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120471 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120471 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120471 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120471 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120471 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120471 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120471 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120471 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120471 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120471 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x0
000120471 9201_ $$0I:(DE-He78)G035-20160331$$kG035$$lTumor- und Serumbank$$x1
000120471 9201_ $$0I:(DE-He78)G825-20160331$$kG825$$lMT NCT Mol. Pathology Core$$x2
000120471 9201_ $$0I:(DE-He78)G835-20160331$$kG835$$lAD Palliative Oncology$$x3
000120471 980__ $$ajournal
000120471 980__ $$aVDB
000120471 980__ $$aI:(DE-He78)L101-20160331
000120471 980__ $$aI:(DE-He78)G035-20160331
000120471 980__ $$aI:(DE-He78)G825-20160331
000120471 980__ $$aI:(DE-He78)G835-20160331
000120471 980__ $$aUNRESTRICTED